Dr Warren Fong Rheumatologist Singapore General Hospital
- +65 6321 4377
- Outram Road, Singapore 169608
Bobby McFarland Consultant Paediatric Neurologist Newcastle leads pioneering clinical and research work in mitochondrial disorders. Professor Bobby McFarland directs the NHS Highly Specialised Service for Rare Mitochondrial Disorders and serves as a consultant paediatric neurologist at the Great North Children’s Hospital in Newcastle. His role involves both cutting-edge research and clinical leadership, helping transform patient care.
Bobby McFarland Consultant Paediatric Neurologist Newcastle began his medical training in paediatrics and paediatric neurology in London and Newcastle upon Tyne. Early on, he studied the molecular consequences and clinical challenges linked to mutations of mitochondrial DNA. This foundation set the stage for his later research breakthroughs.
As Director of the NHS Highly Specialised Service for Rare Mitochondrial Disorders, Bobby leads a dedicated team of clinicians, nurses, and allied health professionals. Together, they diagnose and manage complex mitochondrial diseases. Furthermore, the service ensures patients receive the most advanced care available. This leadership role allows Bobby to directly impact patient outcomes.
Bobby McFarland Consultant Paediatric Neurologist Newcastle integrates research with clinical practice seamlessly. For instance, he leads a national mitochondrial disease patient cohort study involving 1,860 participants. This project advances understanding and accelerates new treatments. Additionally, he facilitates rapid translation of research breakthroughs, such as the innovative IVF technique known as Mitochondrial Replacement Therapy (MRT). Thanks to Wellcome and NHS funding, Bobby offers a clinical research program in this area.
Currently, Bobby holds the titles of Professor of Paediatric Mitochondrial Medicine and Action Medical Research Professor of Neuromuscular Disease at the Wellcome Centre for Mitochondrial Research, Newcastle University. His research focuses on molecular genetics, neuropathology, natural history studies, and clinical trials. In particular, he leads a neurodevelopmental study of children born after mitochondrial replacement therapy. This study provides vital insights into long-term outcomes.
Overall, he remains committed to improving diagnosis and treatment of mitochondrial diseases. His leadership in clinical services and research continually pushes boundaries. Moreover, his work benefits both patients and the wider medical community.
